LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis
Sponsor: Veloxis Pharmaceuticals
Terminated
Study was discontinued due to slow enrollment
Other terminated trials from Veloxis Pharmaceuticals
Other Autoimmune Hepatitis trials with similar outcome
Listed as NCT00608894, this PHASE2 trial focuses on Autoimmune Hepatitis and remains terminated or withdrawn. Sponsored by Veloxis Pharmaceuticals, it has been updated 9 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Feb 2020 — Apr 2020 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Veloxis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .